ZYMFENTRA
Scope
Date
~
-
Bio & Pharma
Celltrion's Zymfentra joins US insurance-covered drug lists
South Korean biosimilar maker Celltrion Inc. said on Monday that its subcutaneous injection formulation for autoimmune diseases, Zymfentra (inflixim...
Aug 06, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion eyes M&A in Europe, $3.3 bn Zymfentra sales: chairman
WASHINGTON, D.C. – South Korean biosimilar giant Celltrion Inc. is accelerating its push to transform into a novel drug developer, going after...
May 23, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion'a autoimmune disease drug Zymfentra makes US debut
South Korean biopharmaceutical giant Celltrion Inc. said on March 17 that it has launched its new autoimmune disease treatment Zymfentra in the US m...
Mar 18, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion ships initial supply of Zymfentra to US
South Korea's Celltrion Inc. announced on Wednesday that it shipped the first supply of its subcutaneous injection type of the autoimmune disease tr...
Feb 29, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare's Remsima SC to be launched in US in 2024
Celltrion Healthcare Co. announced on Thursday that its autoimmune disease treatment Zymfentra (the US product name for Remsima SC) is set to be lau...
Nov 30, 2023 (Gmt+09:00)
Latest News
- 1 HYBE shares fall after NewJeans demand Min's reinstatement
- 2 Hyundai Motor’s IONIQ 5: Pope Francis’ Popemobile in Singapore
- 3 SK E&S considers selling real estate for clean energy
- 4 Celltrion to supply breast, stomach cancer treatment to Brazil
- 5 Shinsegae Department Store expands its diamond business